Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Aptose Biosciences ( (TSE:APS) ).
On July 15, 2025, Aptose Biosciences announced it received a second advance of $2 million from Hanmi Pharmaceutical under an $8.5 million loan agreement to continue developing tuspetinib in triplet therapy for AML. The TUS+VEN+AZA triplet therapy has shown promising antileukemic activity and safety in genetically diverse AML patients, including those with TP53 mutations. The ongoing TUSCANY triplet Phase 1/2 study has demonstrated safety and efficacy in early data, supporting Aptose’s efforts to address unmet medical needs in AML treatment.
The most recent analyst rating on (TSE:APS) stock is a Buy with a C$60.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. The company’s pipeline includes small molecule cancer therapeutics designed to provide single-agent efficacy and enhance the efficacy of other anti-cancer therapies without overlapping toxicities. Its lead compound, tuspetinib, is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML).
Average Trading Volume: 8,045
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$6.38M
For a thorough assessment of APS stock, go to TipRanks’ Stock Analysis page.